Clinical & Translational Genomics | GenomeWeb

Clinical & Translational

Through Navican, patients at Intermountain can get tested on an internally developed NGS platform that gauges a range of actionable genes implicated in cancer. 

The test enables donor screening laboratories to use PCR-based diagnostic technology to screen donated blood and plasma.

The company plans to use Thermo Fisher Scientific's newly launched PharmacoScan array-based platform for its testing.

The company plans to raise $25 million in a Series B financing round. It is also working on a two-color chemistry and aims to develop an instrument for clinical applications.

Under the partnership, Myriad will be ION's preferred partner for providing hereditary testing to its member practices.